Epigenetic  ||| S:0 E:11 ||| JJ
modulation  ||| S:11 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
hematologic  ||| S:25 E:37 ||| JJ
malignancies ||| S:37 E:49 ||| NN
:  ||| S:49 E:51 ||| :
challenges  ||| S:51 E:62 ||| NNS
and  ||| S:62 E:66 ||| CC
progress  ||| S:66 E:75 ||| VB
Genetic  ||| S:75 E:83 ||| JJ
alterations ||| S:83 E:94 ||| NN
,  ||| S:94 E:96 ||| ,
including  ||| S:96 E:106 ||| VBG
gene  ||| S:106 E:111 ||| NN
mutations ||| S:111 E:120 ||| NNS
,  ||| S:120 E:122 ||| ,
and  ||| S:122 E:126 ||| CC
chromosomal  ||| S:126 E:138 ||| JJ
amplifications ||| S:138 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
deletions ||| S:154 E:163 ||| NNS
,  ||| S:163 E:165 ||| ,
inversions ||| S:165 E:175 ||| NN
,  ||| S:175 E:177 ||| ,
and  ||| S:177 E:181 ||| CC
translocations ||| S:181 E:195 ||| NN
,  ||| S:195 E:197 ||| ,
are  ||| S:197 E:201 ||| VBP
hallmarks  ||| S:201 E:211 ||| VBN
of  ||| S:211 E:214 ||| IN
the  ||| S:214 E:218 ||| DT
molecular  ||| S:218 E:228 ||| JJ
biology  ||| S:228 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
cancer ||| S:239 E:245 ||| NN
.  ||| S:245 E:247 ||| .
These  ||| S:247 E:253 ||| DT
events  ||| S:253 E:260 ||| NNS
lead  ||| S:260 E:265 ||| VBP
to  ||| S:265 E:268 ||| TO
oncogene  ||| S:268 E:277 ||| VB
activation ||| S:277 E:287 ||| NNS
,  ||| S:287 E:289 ||| ,
formation  ||| S:289 E:299 ||| NN
of  ||| S:299 E:302 ||| IN
chimeric  ||| S:302 E:311 ||| JJ
oncoproteins ||| S:311 E:323 ||| NN
,  ||| S:323 E:325 ||| ,
and ||| S:325 E:328 ||| CC
/ ||| S:328 E:329 ||| NNP
or  ||| S:329 E:332 ||| CC
inactivation  ||| S:332 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
tumor  ||| S:348 E:354 ||| NN
suppressor  ||| S:354 E:365 ||| NN
genes ||| S:365 E:370 ||| NNS
.  ||| S:370 E:372 ||| .
Such  ||| S:372 E:377 ||| JJ
genetic  ||| S:377 E:385 ||| JJ
changes  ||| S:385 E:393 ||| NNS
contribute  ||| S:393 E:404 ||| VBP
to  ||| S:404 E:407 ||| TO
the  ||| S:407 E:411 ||| DT
neoplastic  ||| S:411 E:422 ||| JJ
transformation  ||| S:422 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
cells ||| S:440 E:445 ||| NNS
,  ||| S:445 E:447 ||| ,
as  ||| S:447 E:450 ||| RB
well  ||| S:450 E:455 ||| RB
as  ||| S:455 E:458 ||| IN
the  ||| S:458 E:462 ||| DT
eventual  ||| S:462 E:471 ||| JJ
acquisition  ||| S:471 E:483 ||| NN
by  ||| S:483 E:486 ||| IN
malignant  ||| S:486 E:496 ||| JJ
cells  ||| S:496 E:502 ||| NNS
of  ||| S:502 E:505 ||| IN
a  ||| S:505 E:507 ||| DT
more  ||| S:507 E:512 ||| RBR
aggressive  ||| S:512 E:523 ||| JJ
biologic  ||| S:523 E:532 ||| NN
and  ||| S:532 E:536 ||| CC
clinical  ||| S:536 E:545 ||| JJ
behavior ||| S:545 E:553 ||| NN
.  ||| S:553 E:555 ||| .
However ||| S:555 E:562 ||| RB
,  ||| S:562 E:564 ||| ,
in  ||| S:564 E:567 ||| IN
recent  ||| S:567 E:574 ||| JJ
years ||| S:574 E:579 ||| NNS
,  ||| S:579 E:581 ||| ,
it  ||| S:581 E:584 ||| PRP
has  ||| S:584 E:588 ||| VBZ
become  ||| S:588 E:595 ||| VBN
apparent  ||| S:595 E:604 ||| JJ
that  ||| S:604 E:609 ||| IN
these  ||| S:609 E:615 ||| DT
genetic  ||| S:615 E:623 ||| JJ
events  ||| S:623 E:630 ||| NNS
are  ||| S:630 E:634 ||| VBP
not  ||| S:634 E:638 ||| RB
the  ||| S:638 E:642 ||| DT
sole  ||| S:642 E:647 ||| JJ
determinants  ||| S:647 E:660 ||| NN
of  ||| S:660 E:663 ||| IN
the  ||| S:663 E:667 ||| DT
biologic  ||| S:667 E:676 ||| JJ
behavior  ||| S:676 E:685 ||| NN
of  ||| S:685 E:688 ||| IN
tumor  ||| S:688 E:694 ||| NN
cells ||| S:694 E:699 ||| NNS
.  ||| S:699 E:701 ||| .
Indeed ||| S:701 E:707 ||| RB
,  ||| S:707 E:709 ||| ,
it  ||| S:709 E:712 ||| PRP
is  ||| S:712 E:715 ||| VBZ
becoming  ||| S:715 E:724 ||| VBG
increasingly  ||| S:724 E:737 ||| RB
apparent  ||| S:737 E:746 ||| JJ
that  ||| S:746 E:751 ||| IN
tumor  ||| S:751 E:757 ||| NN
cells  ||| S:757 E:763 ||| NNS
with  ||| S:763 E:768 ||| IN
a  ||| S:768 E:770 ||| DT
given  ||| S:770 E:776 ||| VBN
genotype  ||| S:776 E:785 ||| RB
exhibit  ||| S:785 E:793 ||| VB
a  ||| S:793 E:795 ||| DT
differential  ||| S:795 E:808 ||| NN
phenotype  ||| S:808 E:818 ||| VBZ
depending  ||| S:818 E:828 ||| VBG
on  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
microenvironment  ||| S:835 E:852 ||| NN
in  ||| S:852 E:855 ||| IN
which  ||| S:855 E:861 ||| WDT
they  ||| S:861 E:866 ||| PRP
reside ||| S:866 E:872 ||| VBD
.  ||| S:872 E:874 ||| .
Furthermore ||| S:874 E:885 ||| RB
,  ||| S:885 E:887 ||| ,
extensive  ||| S:887 E:897 ||| JJ
data  ||| S:897 E:902 ||| NNS
have  ||| S:902 E:907 ||| VBP
shown  ||| S:907 E:913 ||| VBN
that  ||| S:913 E:918 ||| IN
derivative  ||| S:918 E:929 ||| JJ
daughter  ||| S:929 E:938 ||| NN
cells  ||| S:938 E:944 ||| NNS
of  ||| S:944 E:947 ||| IN
neoplastic ||| S:947 E:957 ||| NN
,  ||| S:957 E:959 ||| ,
as  ||| S:959 E:962 ||| RB
well  ||| S:962 E:967 ||| RB
as  ||| S:967 E:970 ||| IN
normal  ||| S:970 E:977 ||| JJ
cells ||| S:977 E:982 ||| NNS
,  ||| S:982 E:984 ||| ,
inherit  ||| S:984 E:992 ||| JJ
changes  ||| S:992 E:1000 ||| NNS
in  ||| S:1000 E:1003 ||| IN
the  ||| S:1003 E:1007 ||| DT
patterns  ||| S:1007 E:1016 ||| NNS
of  ||| S:1016 E:1019 ||| IN
gene  ||| S:1019 E:1024 ||| NN
expression  ||| S:1024 E:1035 ||| NN
that  ||| S:1035 E:1040 ||| WDT
are  ||| S:1040 E:1044 ||| VBP
not  ||| S:1044 E:1048 ||| RB
associated  ||| S:1048 E:1059 ||| VBN
with  ||| S:1059 E:1064 ||| IN
changes  ||| S:1064 E:1072 ||| NNS
in  ||| S:1072 E:1075 ||| IN
the  ||| S:1075 E:1079 ||| DT
primary  ||| S:1079 E:1087 ||| JJ
DNA  ||| S:1087 E:1091 ||| NN
sequence  ||| S:1091 E:1100 ||| NN
but  ||| S:1100 E:1104 ||| CC
are  ||| S:1104 E:1108 ||| VBP
instead  ||| S:1108 E:1116 ||| RB
related  ||| S:1116 E:1124 ||| VBN
to  ||| S:1124 E:1127 ||| TO
changes  ||| S:1127 E:1135 ||| NNS
in  ||| S:1135 E:1138 ||| IN
chromatin  ||| S:1138 E:1148 ||| JJ
structure  ||| S:1148 E:1158 ||| NN
and  ||| S:1158 E:1162 ||| CC
its  ||| S:1162 E:1166 ||| PRP$
accessibility  ||| S:1166 E:1180 ||| NN
for  ||| S:1180 E:1184 ||| IN
transcriptional  ||| S:1184 E:1200 ||| JJ
activity ||| S:1200 E:1208 ||| NN
.  ||| S:1208 E:1210 ||| .
These  ||| S:1210 E:1216 ||| DT
heritable  ||| S:1216 E:1226 ||| JJ
gene  ||| S:1226 E:1231 ||| NN
expression  ||| S:1231 E:1242 ||| NN
changes  ||| S:1242 E:1250 ||| NNS
that  ||| S:1250 E:1255 ||| WDT
are  ||| S:1255 E:1259 ||| VBP
not  ||| S:1259 E:1263 ||| RB
associated  ||| S:1263 E:1274 ||| VBN
with  ||| S:1274 E:1279 ||| IN
changes  ||| S:1279 E:1287 ||| NNS
in  ||| S:1287 E:1290 ||| IN
the  ||| S:1290 E:1294 ||| DT
primary  ||| S:1294 E:1302 ||| JJ
nucleotide  ||| S:1302 E:1313 ||| JJ
sequence  ||| S:1313 E:1322 ||| NNS
are  ||| S:1322 E:1326 ||| VBP
referred  ||| S:1326 E:1335 ||| VBN
to  ||| S:1335 E:1338 ||| TO
as  ||| S:1338 E:1341 ||| RB
epigenetic  ||| S:1341 E:1352 ||| JJ
changes ||| S:1352 E:1359 ||| NNS
.  ||| S:1359 E:1361 ||| .
This  ||| S:1361 E:1366 ||| DT
review  ||| S:1366 E:1373 ||| NN
provides  ||| S:1373 E:1382 ||| VBZ
an  ||| S:1382 E:1385 ||| DT
overview  ||| S:1385 E:1394 ||| NN
of  ||| S:1394 E:1397 ||| IN
the  ||| S:1397 E:1401 ||| DT
regulation  ||| S:1401 E:1412 ||| NN
of  ||| S:1412 E:1415 ||| IN
the  ||| S:1415 E:1419 ||| DT
epigenome  ||| S:1419 E:1429 ||| NN
in  ||| S:1429 E:1432 ||| IN
neoplastic  ||| S:1432 E:1443 ||| JJ
cells ||| S:1443 E:1448 ||| NNS
,  ||| S:1448 E:1450 ||| ,
with  ||| S:1450 E:1455 ||| IN
particular  ||| S:1455 E:1466 ||| JJ
emphasis  ||| S:1466 E:1475 ||| NN
on  ||| S:1475 E:1478 ||| IN
DNA  ||| S:1478 E:1482 ||| NNP
methylation  ||| S:1482 E:1494 ||| NN
and  ||| S:1494 E:1498 ||| CC
histone  ||| S:1498 E:1506 ||| JJ
acetylation  ||| S:1506 E:1518 ||| NN
as  ||| S:1518 E:1521 ||| IN
therapeutic  ||| S:1521 E:1533 ||| JJ
targets  ||| S:1533 E:1541 ||| NNS
for  ||| S:1541 E:1545 ||| IN
hematologic  ||| S:1545 E:1557 ||| JJ
malignancies ||| S:1557 E:1569 ||| NN
.  ||| S:1569 E:1571 ||| .
